IP Library Granted Patent US 9,671,415
Granted Patent B2
US 9,671,415 · App. 14/874,047 · Granted Jun 6, 2017

Immunoassay for pyrrolidinophenones

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,671,415
App. No.
14/874,047
Granted
Jun 6, 2017
Kind
B2
Abstract

The current invention provides an improved immunoassay for the detection and determination of pyrrolidinophenone based designer drugs in hair and biological fluids (urine, blood, and oral fluid). The generic immunoassay is underpinned by novel, sub-family-specific antibodies, which display surprising sensitivity. The invention further describes substrates comprising an antibody that is specific to compounds of the pyrrolidinophenone family. Also described are the novel immunogens from which the antibodies are derived and kits incorporating the antibodies of the current invention.

Claims (8)

1. A polyclonal antibody having 100% cross-reactivity to α-pyrrolidinovalerophenone (α-PVP), greater than 100% cross-reactivity to pyrovalerone, less than 100% but more than 70% cross-reactivity to 3,4-methylenedioxy-α-pyrrolidinopentiophenone (MDPV), α-pyrrolidinopentiothiophenone and naphyrone, and less than 1% cross-reactivity to 3,4-methylenedioxy-α-pyrrolidinopropiophenone (MDPPP), α-pyrrolidinopropiophenone, butylone, 4-fluoromethcathinone, methylone, methedrone, pentylone, and mephedrone, standardized with α-PVP and using Tracer 1, wherein α-PVP is:

and Tracer 1 is 2-(4-(2-(pyrrolidin-1-yl)pentanoyl)phenoxy)acetic acid (PVP 4-CME)-horseradish peroxidase (HRP).

2. The polyclonal antibody of claim 1 , having an IC50 of less than 1 ng/ml for each of α-pyrrolidinovalerophenone (α-PVP), pyrovalerone and 3,4-methylenedioxy-α-pyrrolidinopentiophenone (MDPV).

3. The polyclonal antibody of claim 1 , which has been purified.

4. The polyclonal antibody of claim 3 , wherein the purification is by immunoglobulin precipitation.

5. The polyclonal antibody of claim 1 , wherein the antibody is adsorbed on or attached to a solid state device.

6. A kit comprising the polyclonal antibody of claim 1 .

7. The kit of claim 6 , wherein the polyclonal antibody is adsorbed on or attached to a solid state device.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE NATURE OF CONVENYANCE PREVIOUSLY RECORDED AT REEL: 055950 FRAME: 0471. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Apr 20, 2021
From: RANDOX LABORATORIES LIMITED
To: NORTHERN BANK LIMITED
Reel/Frame 056210/0055 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2021
From: RANDOX LABORATORIES LIMITED
To: NORTHERN BANK LIMITED
Reel/Frame 055950/0471 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2016
From: MCCONNELL, IVAN; FITZGERALD, PETER; LOWRY, PHILIP; BENCHIKH, ELOUARD
To: RANDOX LABORATORIES LIMITED
Reel/Frame 037511/0977 →